In humans, somatosensory stimulation results in increased corticomotoneuronal excitability to the stimulated body parts. The purpose of this study was to investigate the underlying mechanisms. We recorded motor evoked potentials (MEPs) to transcranial magnetic stimulation (TMS) from abductor pollicis brevis (APB), first dorsal interosseous (FDI), and abductor digiti minimi (ADM) muscles. MEP amplitudes, recruitment curves (RC), intracortical inhibition (ICI), intracortical facilitation (ICF), resting (rMT) and active motor thresholds (aMT) were recorded before and after a 2-h period of ulnar nerve electrical stimulation at the wrist. Somatosensory input was monitored by recording somatosensory evoked potentials. To differentiate excitability changes at cortical vs. subcortical sites, we recorded supramaximal peripheral M-responses and MEPs to brainstem electrical stimulation (BES). In order to investigate the involvement of GABAergic mechanisms, we studied the influence of lorazepam (LZ) (a GABA A receptor agonist) relative to that of dextromethorphan (DM) (an NMDA receptor antagonist) and placebo in a double-blind design. We found that somatosensory stimulation increased MEP amplitudes to TMS only in the ADM, confirming a previous report. This effect was blocked by LZ but not by either DM or placebo and lasted between 8 and 20 min in the absence of (i) changes in MEPs elicited by BES, (ii) amplitudes of early somatosensory-evoked potentials or (iii) M-responses. We conclude that somatosensory stimulation elicited a focal increase in corticomotoneuronal excitability that outlasts the stimulation period and probably occurs at cortical sites. The antagonistic effect of LZ supports the hypothesis of GABAergic involvement as an operating mechanism. (Received 31 May 2001; accepted after revision 23 January 2002) protocol was approved by the NINDS Investigational Review Board. All subjects participated in several experiments.
Experimental protocol
Electrophysiological measurement of CM excitability by transcranial magnetic stimulation (TMS) was obtained on different days before and after one of two interventions: (a) a 2-h period of electrical stimulation of the ulnar nerve; and (b) a 2-h idle time (no stimulation). This latter control condition was added because attentional and cognitive factors (Rosler et al. 1999; Rossini et al. 1999) vary during the course of the 2-3-h experiments and can influence corticomotoneuronal excitability. Subjects sat on a comfortable chair during all experiments.
We first identified the optimal position to stimulate the ulnar nerve at the wrist by recording the M-response. Silver-silver chloride electrodes (diameter 10 mm) were then placed with the cathode proximal.
Trains of electrical stimulation were delivered at 1 Hz (Grass stimulator S 8800 with SIU5 stimulus isolation unit, Grass Instrument Division, Astro-Med Inc., West Warwick, RI, USA). Each train consisted of five single pulses of 1 ms duration delivered at 10 Hz (Ridding et al. 2000) . The stimulus intensity was adjusted to elicit small compound muscle action potentials (CMAPs) of 50-100 µV from the ADM in the absence of visible finger movements. This low stimulation intensity and the stimulus duration of 1 ms preferentially activate large cutaneous and proprioceptive sensory fibres (Panizza et al. 1992) . Stimulation was painless, comfortable, and resulted in mild paresthesias in digits 4 and 5 (sometimes also 3). Relaxation during the 2-h period of somatosensory stimulation was monitored by electromyography (EMG). During the stimulation period, subjects remained seated, reading books or magazines of their choice. They were instructed to avoid arm movements. However, they were allowed to change their arm position during the 2-h period if the initial position was no longer comfortable. Supramaximal M-responses were recorded from the abductor pollicis brevis (APB), first dorsal interosseous (FDI), and abductor digiti minimi (ADM) muscles before and after stimulation and idle time.
Somatosensory-evoked potentials (SEPs) during ulnar nerve stimulation were recorded to monitor the stability of the signal arriving in the cerebral cortex. The active recording electrode was placed over C4‚ (2 cm posterior to C4) referenced to Fz (Terao et al. 1999) . EEG activity was pre-amplified, filtered (2 Hz-2 kHz), and stored using a Counterpoint device (see below) and a Labview application (Kaelin-Lang & Cohen, 2000) . Peak-to-peak amplitudes of components N20-P25 and P25-N33, thought to reflect arrival and initial cortical processing of somatosensory input (Allison et al. 1991; Cheron et al. 2000) , were measured during and after the 2-h stimulation period.
Transcranial magnetic stimulation
Motor evoked potentials (MEPs) were recorded from APB, FDI, and ADM muscles using silver-silver chloride electrodes in a tendon belly arrangement on the non-dominant left hand. EMG was pre-amplified and band-pass filtered (10 Hz-2 kHz) using a Dantec Counterpoint electromyograph (Dantec Electronics, Skovlunde, Denmark). Input was then fed into an IBM compatible personal computer (486DX) with a Keithley DAS-1600 I/O board controlled by an 'Asyst' application (Keithley, Taunton, MA, USA) or to a computerized data acquisition system built with the Labview graphical programming language (sampling rate 5 kHz) (Kaelin-Lang & Cohen, 2000). Its 'conditional triggering' feature was used to deliver TMS stimuli only when target muscles (one to three depending on the experiment) were relaxed. Relaxation was defined as EMG activity at baseline < 40 µV peak-to-peak amplitude for at least 1 s. MEP amplitude was expressed relative to the maximal peripheral M-responses. TMS was delivered to the optimal scalp position (right motor cortex) to stimulate the target muscle. TMS was delivered through a figure-of-eightshaped magnetic coil (outside diameter 8.7 cm) connected to a Quad-module and two Magstim 200 magnetic stimulators (The Magstim Company, Dyfed, UK). The magnetic coil was placed tangentially to the scalp, with the intersection of both wings at a 45 deg angle with the midline to optimally stimulate the motor cortex (Brasil-Neto et al. 1992; Mills et al. 1992) .
Measures of corticomotoneuronal excitability
Resting motor thresholds. The resting motor threshold (rMT) was defined as the minimum TMS intensity (measured to the nearest 1 % of the maximum output of the magnetic stimulator) required to elicit at least five out of 10 MEP ≥ 50 mV in consecutive trials (Rossini et al. 1994) . TMS stimulus intensities were expressed relative to rMT measured from the ADM. There were no statistically significant differences between rMT from the ADM, APB and FDI. The active motor threshold (aMT) was defined as the minimum TMS intensity (measured to the nearest 1 % of the maximum output of the magnetic stimulator) required to elicit at least five out of 10 MEPs ≥ 100 mV in consecutive trials during background muscle facilitation (5 % maximal isometric muscle contraction of the ADM; see Kaelin-Lang & Cohen, 2000) .
Recruitment curves.
Mean MEP amplitudes were obtained in response to 10 TMS stimuli delivered at each of four stimulus intensities: 10, 20, 30 and 40 % above rMT in 10 subjects. In three subjects who demonstrated a significant increase in MEP amplitude in this first experiment, recruitment curves were also obtained at 10 randomly intermixed stimulus intensities (step of 5 % absolute stimulator output, six stimuli at each intensity). Based on these data, a nonlinear regression analysis was implemented using the Levenberg-Marquard least-mean-squares algorithm with the Boltzmann function (Devanne et al. 1997; Kaelin-Lang & Cohen, 2000) :
This function is used to relate the amplitude of the response (MEP a ) to the TMS stimulation intensity (I) and has three different parameters: the function plateau (P), the stimulus intensity (I 50 ) required to obtain an MEP amplitude 50 % of the plateau, and the slope parameter k, which is related to the maximal function steepness (Devanne et al. 1997) .
Intracortical inhibition and facilitation. Intracortical inhibition (ICI) and intracortical facilitation (ICF) were measured with paired-pulse TMS as previously described (Kujirai et al. 1993; Ziemann et al. 1996) . Briefly, active motor thresholds (aMT) were determined first. Conditioning stimulus intensity was then set to 90 % of the aMT. The intensity of the test stimulus was that required to evoke MEPs of approximately 1 mV (often close to 40 % above rMT). The order of presentation of inhibitory (2 ms), excitatory (15 ms) and control trials (test stimulus alone) intervals was randomized. Six to eight trials were recorded for each ISI.
Brainstem electrical stimulation.
A previous study evaluating the effects of a 2-h period of somatosensory stimulation on the responses to TMS and TES under muscle facilitation did not allow identification of the site of the excitability changes (Ridding et al. 2000) . For this reason, we opted to study responses to brainstem electrical stimulation (BES). We compared motor potentials evoked by BES (Ugawa et al. 1991) with those evoked by TMS in two subjects with a documented increase in TMS-evoked MEPs. MEPs induced in response to TMS and BES were recorded before and after the 2-h period of somatosensory stimulation. The order of presentation of TMS and BES stimuli was randomized. BES was delivered through surface electrodes from a Digitimer D180 electrical stimulator (Digitimer Ltd, Hertfordshire, UK). Stimulating electrodes in a bipolar montage were fixed with collodion on the skin overlying the mastoids (Ugawa et al. 1991) . MEPs induced in response to TMS (10) and BES (5) were stored for off-line analysis. Interval between stimuli varied randomly between 7 and 12 s. Because BES is a painful procedure, only two subjects were studied.
Effects of lorazepam and dextromethorphan
We investigated the effects of systemic administration of lorazepam (LZ), a benzodiazepine that facilitates g-aminobutyric acid A (GABA A ) receptor-mediated inhibition (Macdonald & Kelly, 1995) and of dextromethorphan (DM), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist (Apland & Braitman, 1990 ) on the increased corticomotor excitability elicited by somatosensory stimulation. Both drugs were administered in a placebo-controlled double-blind design in separate sessions.
Lorazepam. Pre-and post-intervention measures were obtained at a time when calculated drug levels were therapeutic. Testing was first performed 2 h following intake of a single oral dose of LZ (0.038 mg kg _1 orally) in five subjects. At this time, blood levels are expected to be within the therapeutic range and remain there for 3-5 h (Greenblatt et al. 1993) . A pharmacokinetic computer simulation that assumes a two-compartment model with firstorder oral absorption (Gupta et al. 1990 ) was performed for each subject (considering individual LZ dose and body weight) to estimate concentrations before, during, and after the 2-h period of somatosensory stimulation (WinNonlin v1.5, Pharsight, Mountain View, CA, USA). Results indicated that LZ concentrations exceeded 42.9 ng ml _1 , well above therapeutic levels (Greenblatt et al. 1989) in all individuals and intervals tested (range: 42.9-56 mg l _1 ).
Dextromethorphan. Since DM (2 mg kg _1 orally) rapidly reaches therapeutic blood levels and has a relatively short half-life (2.5 h) (Hollander et al. 1994 ), a single oral dose was administered 30 min preceding the 2-h period of somatosensory stimulation in six subjects. DM at this dose results in serum and brain concentrations in humans (Hollander et al. 1994; Steinberg et al. 1996) similar to those that induce NMDA receptor block in vitro (Apland & Braitman, 1990 ). Since DM is rapidly metabolized to dextorphan, a similarly active compound (Hollander et al. 1994) , and brain tissue DM and dextorphan concentrations are much higher than those present in blood (Steinberg et al. 1996) , DM plasma levels are an imprecise indicator of CNS action (Hollander et al. 1994 ) and were not calculated.
Placebo.
Placebo was given at exactly the same time as the active drugs. Because the time of intake was not the same for DM and for LZ, each drug had its own placebo session. Side-effects were rated according to the subjects' self-report as absent, minimal, mild or moderate.
Statistical analysis 'GB-Stat' software (Dynamic Microsystems, Silver Spring, MD, USA) and ad hoc Labview applications were used for statistical analysis. Effects of somatosensory stimulation on MEP amplitudes recorded at four different stimulus intensities were compared using repeated measures ANOVA with two within-subject factors:
'time' (before and after intervention) and 'intensity' (four levels). The focality of the effect was analysed with a two-way ANOVA model with factors 'muscle' (three levels) and 'time' (before and after intervention), and the time course experiment with a oneway ANOVA (factor 'time', four levels). Student's t test and the Wilcoxon test were used for post-hoc testing. Recruitment curves were analysed using a nonlinear regression analysis (Capaday et al. 1999) followed by F-test statistics (Motulsky & Ransnas, 1987) . The significance level was set to P < 0.05 after correction for multiple comparisons, when required. All results are given as means ± standard error of the mean (S.E.M.). All ANOVA results are given with the degree of freedom (d.f.) and the F value.
RESULTS

Effects of somatosensory stimulation on corticomotoneuronal excitability
A 2-h period of somatosensory stimulation of the ulnar nerve resulted in significantly increased MEP amplitude srecorded from the ulnar nerve-innervated ADM muscle (ANOVA, main factor 'time', d.f. = 1, F = 7.91, P < 0.01), while the control intervention failed to elicit this effect (Fig. 1 ).
In the absence of a significant interaction between factors 'time' and 'intensity' (ANOVA, d.f. = 3, F = 0.8, P = 0.48), the MEP amplitude increase was more pronounced at higher levels of stimulation. At 40 % above rMT (Fig. 1B) MEP amplitudes variably increased in 8 of 10 subjects (on average by 67.8 ± 23.4 %, range _13 % to +252 %, n = 10). As expected, ADM amplitudes were significantly higher at higher stimulation intensities (ANOVA, main factor 'intensity', d.f. = 3, F = 3.44, P < 0.05).
A more detailed analysis of recruitment curves (Devanne et al. 1997) showed that both the plateau (P) (P before: 33.8 % M-response; after: 42.4 % M-response) and the I 50 parameters (I 50 before: +62.4 % above rMT; after: +53.4 % above rMT) of the recruitment curve were changed by somatosensory stimulation while the slope parameter k remained unchanged (k before: 20.3; after: 21) (Fig. 1C) .
The intersession variability of this effect (measured with the coefficient of variation) within individuals who participated in three or more experiments (maximum six) ranged between 9.8 and 49.8 % (average 28.3 %, n = 5 subjects).
The 2-h period of somatosensory stimulation did not significantly influence: (a) ADM rMT (before: 45.1 ± 1.2 %; after: 45.1 ± 1.2 %, n = 21); (b) ADM aMT (before: 36.3 ± 1.6 %; after: 36.7 ± 1.4 %, n = 9); (c) intracortical inhibition (ICI) (ICI before: 47.4 ± 14 %, ICI after: 50.9 ± 8.9 %); or (d) intracortical facilitation (ICF) (ICF before: 158.9 ± 10.9 %; ICF after: 186.4 ± 42.9 %, n = 5). Post-hoc power analysis of these data demonstrated that for a power of 80 % with an alpha error of 5 %, our data allowed detection of changes as small as 1 % in rMT and 5 % in aMT (absolute stimulator's output) but only 35 % in ICI and 115 % in ICF.
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Focality of excitability changes elicited by somatosensory stimulation
In contrast to the MEP amplitudes recorded from the ADM, MEP amplitudes simultaneously recorded from the APB muscle, which is innervated by the unstimulated median nerve, remained unchanged by both the 2-h period of somatosensory stimulation and the control intervention (2-h idle time) (Fig. 2) . These results were reproducible in a separate experiment: MEPs were simultaneously recorded from the FDI, APB, and ADM at a TMS intensity 40 % above rMT before and after a 2-h period of somatosensory stimulation. Baseline amplitude of MEPs recorded from the APB and FDI were often higher than from the ADM (ANOVA, main factor 'muscle', d.f. = 2, F = 3.5, P < 0.05, Fig. 3C and D) .
Stimulation resulted in a highly significant increase in MEP amplitude (factor 'time', d.f. = 1, F = 16.5, P < 0.001). This effect was significantly different between muscles (interaction between factor 'time' and 'muscle': d.f = 2, F = 4.16, P < 0.05). The increase in amplitude of MEP recorded from the ulnar nerve-innervated ADM (by +136 ± 84.1 % of the M-response), while variable (Fig. 3D) , was significantly higher than the increase in MEP amplitude recorded from both the APB and FDI (which receives motor innervation from the ulnar nerve but lies in a hand region with median and radial nerve-mediated somatosensory innervation) (Fig. 3) .
Duration of excitability changes elicited by somatosensory stimulation. The duration of this effect was investigated in six subjects. Twenty TMS stimuli (interstimulus intervals 5-7 s) were delivered at an intensity of 40 % above rMT before and at three different and perform TMS measurements. To account for these interindividual differences, we grouped the data into three time intervals: 8-20, 21-35 and 36-50 min. rMT remained unchanged. Factor 'time' was significant (ANOVA, d.f. = 3, F = 3, P < 0.01). Post-hoc pair-wise comparisons revealed that MEPs recorded during the first period were significantly larger than baseline (+173 ± 51%, Fig. 4 ) while MEP amplitudes in the later time intervals only showed a nonsignificant trend towards increase (+55 ± 15 and +42 ± 21%, respectively; see Fig. 4 ).
Site of changes in motor excitability.
A 2-h period of somatosensory stimulation that resulted in increases in TMS-evoked MEP amplitudes did not change amplitudes and areas of the MEPs to BES (Fig. 5) or maximal peripheral M responses (17.9 ± 3.4 mV before and 18.2 ± 3.7 mV after stimulation, n = 10).
Effects of LZ and DM
Administration of a single oral dose of LZ significantly blocked the enhancing effects of a 2-h period of somatosensory stimulation on ADM MEP amplitude (ratio of ADM amplitudes before and after stimulation under LZ: 91.4 ± 12.4 %, n = 5; Fig. 6 ) while placebo did not modify the enhancing effect seen in the drug-naive sessions (ratio of ADM amplitudes before and after stimulation: 185.1 ± 37.8; Fig. 6 ; see Figs 1-3 for comparison). MEP amplitudes recorded from APB were similar under LZ before and after the 2-h period of somatosensory stimulation (ratio of APB amplitudes before and after stimulation: 97 ± 5.0 %), suggesting stability of corticomotoneuronal excitability under LZ.
In contrast, the enhancing effects of a 2-h period of somatosensory stimulation on ADM MEP were unchanged by DM. There was no significant difference between the DM (ratio of ADM amplitudes before and after stimulation under DM: 168.3 ± 26.8 %; Fig. 6 ) and the corresponding placebo session (ratio of ADM amplitudes before and after stimulation: 143.9 ± 10.8 %; Fig. 6 ). Because one subject, experiencing side-effects after DM, was unable to relax, electrophysiological data from only five subjects were analysed.
The amplitude of SEP components N20-P25 and P25-N33 recorded during somatosensory stimulation was similar during DM, LZ and placebo sessions, indicating a stable input into somatosensory cortical regions during each intervention (Fig. 7) . Moreover, SEP amplitudes remained stable within each session: in both placebo sessions (N20-P25 early/late: 3.12 ± 0.42 mV/3.77 ± 0.36 mV; P25-N30: 3.44 ± 0.68 mV/3.58 ± 0.43 mV), DM session (N20-P25 early/late: 3.27 ± 1 mV/3.63 ± 0.8 mV.; P25-N30: 3.47 ± 1 mV/2.4 ± 0.4 mV) and LZ session (N20-P25 early/late: 2.79 ± 0.5 mV/3.39 ± 0.4 mV; P25-N30: 3.26 ± 0.8 mV/3.35 ± 0.9 mV).
Drowsiness was reported under LZ in all five subjects tested (three minimal, one mild, one moderate), under DM in 3/6 subjects (two minimal, one mild) and under Somatosensory stimulation and corticomotor excitability J. Physiol. 540.2
Figure 2. Changes induced by a 2-h period of somatosensory stimulation or 2 h idle time on the amplitude of motor-evoked potentials (MEPs) recorded from the median nerve-innervated abductor pollicis brevis (APB)
A, the amplitude of MEPs (mean ± S.E.M.) recorded at TMS intensities 10, 20, 30 and 40 % above motor threshold from APB were not significantly changed by the 2-h period of electrical stimulation of the ulnar nerve (1----1: before intervention; •--•: after 2-h period of somatosensory stimulation; n = 10 subjects). All amplitudes are expressed as a percentage of the supramaximal M-response. B, a control period consisting of a 2-h idle time (without somatosensory stimulation) did not significantly change the amplitude of MEPs (mean ± S.E.M.) recorded from the APB at TMS intensities 10, 20, 30 and 40 % above motor threshold (1----1: before the 2-h idle time; •--•: after 2-h period of idle time; n = 6). placebo in 2/10 subjects (both minimal). Additionally, DM elicited dizziness in 3/6 subjects (one minimal, one mild, one moderate) and nausea in 2/6 subjects (one minimal, one mild).
DISCUSSION
The new findings of this study are that changes in corticomotoneuronal excitability elicited by a period of somatosensory stimulation occur at supraspinal sites and are markedly influenced by GABAergic mechanisms.
It has been proposed that administration of peripheral somatosensory stimulation is a useful adjuvant therapy to promote recovery of motor function in stroke patients (Johansson et al. 1993; Hamdy & Rothwell, 1998; Powell et al. 1999; Wong et al. 1999; Conforto et al. 2002) . This idea led to studies that demonstrated and characterized changes in corticospinal excitability associated with this form of stimulation in healthy subjects (Hamdy et al. 1998; Ridding et al. 2000; Stefan et al. 2000) . However, the mechanisms underlying this phenomenon are incompletely understood. To address this issue, we utilized a previously described A. Kaelin-Lang and others 628 J. Physiol. 540.2
Figure 3. Comparison of the effect of a 2-h period of somatosensory stimulation on motor evoked potential (MEP) amplitudes simultaneously recorded from the abductor digiti minimi (ADM), abductor pollicis brevis (APB) and first dorsal interosseus (FDI)
A, the 2-h period of electrical stimulation of the ulnar nerve typically induced sensation in a region (hatched area) overlapping the ulnar nerve-innervated ADM but not the ulnar nerve-innervated FDI and the median nerve-innervated APB. B, grand average across all subjects (n = 6) of the individually normalized increase in MEP amplitude (MEP peak-to-peak amplitude before intervention set to 100 %) after a 2-h period of somatosensory stimulation. Only MEP amplitude recorded from the ADM was significantly (P < 0.05) larger after the 2-h period of electrical stimulation. C, representative 3-MEP averages from a typical experiment before the intervention (thin line) and after the intervention (thick line) simultaneously recorded from the ADM, FDI (middle trace) and APB (traces on the right-hand side). D, MEP amplitudes (expressed as percentages of the maximal peripheral M-response) recorded from the ADM, FDI and APB, before (dots on the left of each line) and after (dots on the right of each line) a 2-h period of somatosensory stimulation in all six subjects (each line is one experiment). The individually normalized MEP amplitude (as a percentage of pre-intervention values: MEP peak-to-peak amplitude before intervention set to 100 %) was only significantly larger than baseline in the 8-to 20-min period following the intervention. *P < 0.05.
protocol in which measures of corticomotoneuronal excitability are tested before and after a 2-h period of electrical stimulation of the ulnar nerve leading to increased MEP amplitudes (Ridding et al. 2000) . Consistent with this previous report, we identified an increased MEP amplitude in response to TMS elicited by a 2-h period of somatosensory stimulation in the absence of changes in the unstimulated control condition (2 h idle time). A more detailed analysis of the input-output curves (Devanne et al. 1997) , a sensitive measure of corticospinal excitability (Ridding & Rothwell, 1997; Boroojerdi et al. 2001) , further substantiated this finding. The factors influencing the interindividual and intersession variability demonstrated in this study remain to be determined.
Additionally, we found no changes in rMT, aMT, ICI or ICF. While our study was powered to identify small changes in rMT and aMT, we could only expect to detect changes larger than 35 % in ICI and 115 % in ICF. Therefore, more subtle modifications in ICI and ICF as a consequence of somatosensory stimulation would not be apparent.
While MEP amplitudes from the ulnar nerve-innervated ADM increased, those recorded from the median nerveinnervated APB did not. Interestingly, MEP amplitudes from the FDI remained unaffected by ulnar nerve stimulation. Motor output and muscle afferents to and from FDI are conducted through the ulnar nerve, while cutaneous and joint afferents are carried through the median and radial nerves (see Rossini et al. 1996) . Therefore, electrical stimulation of the ulnar nerve stimulated muscle afferents from the FDI. This stimulation failed to elicit significant changes in MEP amplitudes from this muscle.
These findings suggest a focal somatotopic effect in which somatosensory inputs other than muscle afferents are important for mediating the corticomotoneuronal excitability changes observed in our study, an observation consistent with previous reports (Rossini et al. 1996; Rossi et al. 1998) .
Site of the corticospinal excitability changes
Excitability changes mediating these results can occur at cortical and/or subcortical sites. To address this issue, we recorded MEPs in response to TMS and to BES, as well as maximal peripheral M responses before and after the 2-h stimulation period. This intervention did not modify the amplitude of maximal peripheral M responses or MEPs in response to BES, suggesting the lack of significant excitability changes at muscle, neuromuscular junction or spinal cord structures below the brainstem level, an interpretation consistent with the previously reported stability of F-waves (Ridding et al. 2000) . In contrast, somatosensory stimulation resulted in substantial amplitude increase in MEPs in response to TMS. TMS stimulates predominantly corticocortical connections targeting pyramidal tract neurons (Day et al. 1989; Ridding & Rothwell, 1997; Cracco et al. 1999) whereas BES excites (eliciting only one descending volley) descending motor axons directly at the brainstem level (Ugawa et al. 1991) . Taken together, these findings indicate that a sustained period of somatosensory stimulation exerts its modulatory effect on motor excitability predominantly in the motor cortex. However, we cannot exclude weaker concomitant changes in excitability at the spinal level.
The sensorimotor interactions leading to this change in motor cortical excitability could occur in different cortical and/or subcortical structures and only secondarily influence the motor cortex excitability. First, it is conceivable that the stimulation period elicited increased excitability in the somatosensory 'ventrolateral pars oralis' thalamic nucleus or in the primary somatosensory cortex. However, the stability of SEP amplitudes during the stimulation period argues against this hypothesis. It is also unlikely that the 'ventrolateral pars caudalis' thalamic nucleus which also receives somatosensory information and is linked by direct projections to the primary motor cortex, is the site for such interaction because the connections between this thalamic nucleus and the primary motor cortex are diffuse (Asanuma et al. 1980) and therefore cannot explain the focality of the effect described here. It is more plausible that the site of this interaction is the motor cortex itself which receives somatotopically organized projections from the primary somatosensory cortex in animals (Kaneko et al. 1994a,b) and humans (Terao et al. 1999 ) that participate in learning new motor skills (Pavlides et al. 1993) . It is also possible that other structures of the motor system which receive somatotopically organized somatosensory inputs (e.g. cerebellum or premotor cortical areas) are involved in this sensorimotor interaction.
Candidate mechanisms
GABA, the main inhibitory neurotransmitter in the brain, is actively involved in experience-dependent cerebral reorganization (Zheng & Knudsen, 1999; Feldman, 2000) . As an example, changes in somatosensory input elicited by nerve transection result in rapid modifications in cortical maps that are associated with reduced GABA levels (Garraghty et al. 1991; Myers et al. 2000) . In the motor cortex, similarly rapid changes in motor maps are mimicked by injection of the GABA antagonist bicucculine (Jacobs & Donoghue, 1991) . In humans, deafferentation-induced changes in motor cortex excitability (Ziemann et al. 1998) are also associated with decreased cortical GABA (Levy et al. 1999) . Overall, it is conceivable that a modulation of cortical GABAergic neurotransmission mediates the changes described in this study. Our results demonstrated that a pharmacological manipulation that enhances GABAergic function (Macdonald & Kelly, 1995) blocked changes in corticomotoneuronal excitability elicited by somatosensory stimulation, providing support for this hypothesis. The same pharmacological approach has been successfully utilized to identify the involvement of GABAergic influences on deafferentation-induced plasticity (Ziemann et al. 1998 ) and use-dependent plasticity (Bütefisch et al. 2000) .
In contrast, our results showed that DM did not modify excitability changes elicited by a 2-h period of somatosensory stimulation. 1996) similar to those that induce NMDA receptor block in vitro (Apland & Braitman, 1990) , and elicits side-effects similar to those observed in our study which are consistent with active NMDA receptor block action (Hollander et al. 1994; Steinberg et al. 1996) . The lack of effect of DM observed in this study contrasts with the strong antagonistic effects of identical doses of DM on use-dependent plasticity induced by training in humans (Butefisch et al. 2000) . These results suggest that long-or short-term potentiation-like mechanisms thought to be operational in the setting of use-dependent plasticity (Butefisch et al. 2000) are less involved in excitability changes elicited by somatosensory stimulation. Experiments in animal models are required to gain additional insight on this issue.
The amplitude and latency of early cortical components of SEP to ulnar nerve stimulation under the effects of LZ, did not differ from those obtained under placebo or DM, suggesting stable somatosensory input across conditions. Additionally, attentional levels across conditions were comparable, a conclusion also supported by the lack of amplitude changes in the N30 component of SEP, known to be modulated by mental activity (Cheron & Borenstein, 1992) . Pre-(baseline) and post-intervention MEPs were recorded at a time when the pharmacokinetic computer simulation demonstrated stable therapeutic concentrations of LZ (see Methods). Finally, it is unlikely that the effect of LZ was mediated by nonspecific sedative effects only, since both DM and LZ produced qualitatively similar drowsiness but only LZ blocked motor excitability changes. Hence, the changes in motor cortical excitability induced by a 2-h period of somatosensory stimulation are predominantly influenced by GABAergic function, and much less affected, if at all, by NMDA receptor function. This finding is consistent with the hypothesis that a 2-h period of somatosensory stimulation may modulate GABAergic cortical function, decreasing cortical GABAergic inhibition. Such a decrease is known to facilitate plasticity in animals (Jacobs & Donoghue, 1991) and in humans (Ziemann et al. 2001) and may be a factor contributing to better functional recovery observed when physical therapy is performed in association with somatosensory stimulation after stroke (Johansson et al. 1993 ).
In conclusion, this study demonstrates that a sustained period of nonpainful peripheral electrical stimulation increases corticomotoneuronal excitability, most likely by acting somatotopically in the motor cortex, and is significantly influenced by GABAergic function.
